FROM PUBLIC EVENTS · 2026-11-18

Current stage

  1. Discovery · preclinical
  2. Early clinical · first deals
  3. Late clinical · capacity
  4. Commercial · sales
  1. Global approvals · expansion
  2. M&A · integration
  3. Pipeline reshaping

Early clinical · first deals Has released 24-month Korean Phase 1/2a results for its Parkinson's cell therapy TED-A9 and is preparing a US late-stage trial. Also seen: Global approvals · expansion

  • Released 24-month follow-up results from the TED-A9 Phase 1/2a trial. Source
  • Announced its participation in BIO USA 2026 to seek global partners. Source

Roles often seen at this stageClinical & PV · Regulatory affairs · Manufacturing & MSAT

Companies at the same stage and their people flow →

← Company library
Korea / Company briefSources checked 2026-11-18

S.Biomedics

A company developing stem-cell-based treatments for neurological and intractable diseases, led by TED-A9, an embryonic-stem-cell-derived cell therapy for Parkinson's disease.

TED-A9

Phase 2

A therapy of midbrain dopaminergic progenitors differentiated from human embryonic stem cells; 24-month follow-up of 12 patients in a Korean Phase 1/2a trial is complete.

TED-A9 US late-stage program

Stage unconfirmed

Completed a Pre-IND meeting with the US FDA in October 2025; Catalent handles technology transfer for US manufacturing.

Completion reported

Released 24-month follow-up results from the TED-A9 Phase 1/2a trial.

Completion reported

Attended BIO USA 2026 to hold partnering meetings on TED-A9.

Completion reported

Raised about KRW 40 billion to prepare for Phase 3.

Official role guide

S.Biomedics careers

Current availability unconfirmed

Observed 2026-11-18

Work
Unconfirmed — The official careers page could not be confirmed.
Experience & requirements
Unconfirmed — The official careers page could not be confirmed.

Information from a role guide does not establish a current vacancy.

Sources & coverage 2

A brief based on selected official material, not an exhaustive product or vacancy list.

  1. 에스바이오메딕스, 파킨슨병 세포치료제 'TED-A9' 임상 1/2a상 24개월 추적관찰 결과 공개 ↗서울신문 · Published 2026-06-15 · Sources checked 2026-11-18 · Original unavailable
  2. 에스바이오메딕스, 바이오 USA 참가 "TED-A9, 美 상업화 임상 직행 추진" ↗머니투데이 · Published 2026-06-17 · Sources checked 2026-11-18 · Original unavailable